To determine if GCN2 is a potential therapeutic target for PAH treatment, we first conducted immunofluorescence staining with anti-Thr899 phospho-GCN2 in rat lungs challenged with monocrotaline (MCT). This evidence concerns the gene EIF2AK4 and pulmonary arterial hypertension.